CBLB and cancer: Moreover, the anticoagulant warfarin was found to exert antimetastatic activity via Cbl-b/TAM receptors through NK cells, suggesting that the TAM/Cbl-b inhibitory pathway may be the druggable target for awakening the NK cells to kill cancer metastases.